Rivaroxaban – a safe therapeutic option in patients with antiphospholipid syndrome? Our experience in 23 cases

In the therapeutic approach to patients with antiphospholipid syndrome (APS) with thrombotic manifestations, oral vitamin K antagonists (VKA) remain the standard of care. However, the use of VKA is very often associated with inability to achieve a therapeutic dose even in patients maintaining nutrit...

Descripción completa

Detalles Bibliográficos
Autores principales: Haładyj, Ewa, Olesińska, Marzena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie 2016
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4967983/
https://www.ncbi.nlm.nih.gov/pubmed/27504026
http://dx.doi.org/10.5114/reum.2016.61217

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4967983/
https://www.ncbi.nlm.nih.gov/pubmed/27504026
http://dx.doi.org/10.5114/reum.2016.61217

Ejemplares similares